bioRxiv Science⌕ Search

Biology subjects

Redenti, B.

Publications and source records attributed to Redenti, B..

2 recordsLinked to original sources

Age determines NK cell fate and tissue compartmentalization to CMV infection

Cytomegalovirus (CMV), a ubiquitous herpesvirus, establishes persistent infection that is controlled by both NK and CD8 T cells. While immunity to CMV is primarily studied in adult mice and humans, most individuals acquire CMV during the early years of life and virus-specific NK and T cell responses during this vulnerable life stage are understudied. Here, we show distinct responses by infant and adult NK cells to CMV infection in both mice and humans resulting from cell-intrinsic features and host T cell responses. Infant mice sustained higher viral loads compared to adults following MCMV infection and exhibited non-redundant requirements for NK cells. Infant MCMV-reactive (Ly49H+) NK cells preferentially expanded adaptive-like subsets which were maintained in tissues and exhibited a distinct transcriptional profile relative to adult NK cells. This biased differentiation of adaptive-like NK cells was altered over age and controlled in part, by competition with memory T cells. We demonstrate similar dynamics with human NK cells; distinct adaptive-profiles for HCMV-reactive NK cells in early life and childhood that change over age and are inversely associated with anti-viral T cell responses. Together, our results reveal that NK cells develop adaptive-like responses and seed tissues in early life to provide protective memory when T cell immunity is limited. ONE-SENTENCE SUMMARYMemory NK cell generation to cytomegalovirus infection is regulated by age and T cell immunity

immunology↗

Probiotic neoantigen delivery vectors for precision cancer immunotherapy

Microbial systems have been synthetically engineered to deploy therapeutic payloads in vivo1-4. With emerging evidence that bacteria naturally home to tumors5-7 and modulate anti-tumor immunity8,9, one promising application is the development of bacterial vectors as precision cancer vaccines10-12. In this study, we engineered probiotic E. coli Nissle 1917 (EcN) as an anti-tumor vaccination platform optimized for enhanced production and cytosolic delivery of neoepitope-containing peptide arrays, with increased susceptibility to blood clearance and phagocytosis. These features enhance both safety and immunogenicity, achieving a system which drives potent and specific T cell-mediated anti-cancer immunity that effectively controls or eliminates tumor growth and extends survival in advanced murine primary and metastatic solid tumors. We demonstrate that the elicited anti-tumor immune response involves extensive priming and activation of neoantigen-specific CD4+ and CD8+ T cells, broader activation of both T and NK cells, and a reduction of tumor-infiltrating immunosuppressive myeloid and regulatory T and B cell populations. Taken together, this work leverages the advantages of living medicines to deliver arrays of tumor-specific neoantigen-derived epitopes within the optimal context to induce specific, effective, and durable systemic anti-tumor immunity.

synthetic biology↗